HLB TherapeuticsHLB테라퓨틱스

HLB Therapeutics shows sharp share price gains over three months, but the company is still loss-making with heavy borrowings.

Trailing twelve-month revenue is about ₩64.4B, with an operating loss of ₩9.3B and a net loss of ₩18.0B as of H1 2026. Cash of ₩11.2B sits against borrowings of ₩36.3B, and free cash flow is negative at ₩4.7B. The filings and headlines in the data focus on capital and convertible bond activity and on the RGN-259 drug programme ahead of a planned US Phase 3 trial.

What stands out

• Revenue rose to ₩69.6B in 2025 from ₩54.9B in 2024 (up 26.6%), but operating losses narrowed only to ₩3.5B from ₩7.6B and the operating margin stayed negative at -5.1%.
• Net loss in 2025 was ₩9.2B, much smaller than the ₩22.8B loss in 2024, while the share price is down 14.8% over one year but up 58% over three months.
• Borrowings of ₩36.3B are well above cash of ₩11.2B, and liabilities are 30.5% of equity by the company's own ratio.
• Recent filings include several 5%+ holding reports, conversion price adjustments, a rights offering amendment and convertible bond transactions, which point to ongoing financing activity.
• A Chosun Biz headline from 16 October 2026 describes the company's aim to stage a comeback with RGN-259 ahead of a US Phase 3 trial; the data does not give trial timing or results.

What to watch

• Upcoming full-year 2026 results and whether operating losses narrow from the H1 2026 trailing figures.
• Further filings on conversion price adjustments, convertible bonds, rights offerings or major shareholder changes, since foreign ownership fell from 3.7% to 2.5% over the past 60 days.
• Progress on the RGN-259 US Phase 3 trial, which the data does not describe in detail.